Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABL1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ABL1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ABL1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ABL1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010810112 | Thyroid | PTC | regulation of cell-substrate adhesion | 113/5968 | 221/18723 | 1.87e-09 | 5.28e-08 | 113 |
GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
GO:003010020 | Thyroid | PTC | regulation of endocytosis | 108/5968 | 211/18723 | 3.92e-09 | 1.04e-07 | 108 |
GO:0001558111 | Thyroid | PTC | regulation of cell growth | 188/5968 | 414/18723 | 4.13e-09 | 1.09e-07 | 188 |
GO:1901214113 | Thyroid | PTC | regulation of neuron death | 151/5968 | 319/18723 | 4.74e-09 | 1.24e-07 | 151 |
GO:0051893111 | Thyroid | PTC | regulation of focal adhesion assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:0090109111 | Thyroid | PTC | regulation of cell-substrate junction assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:0045860111 | Thyroid | PTC | positive regulation of protein kinase activity | 176/5968 | 386/18723 | 8.89e-09 | 2.17e-07 | 176 |
GO:0006469111 | Thyroid | PTC | negative regulation of protein kinase activity | 107/5968 | 212/18723 | 1.24e-08 | 2.96e-07 | 107 |
GO:1901216113 | Thyroid | PTC | positive regulation of neuron death | 58/5968 | 97/18723 | 1.32e-08 | 3.11e-07 | 58 |
GO:007050717 | Thyroid | PTC | regulation of microtubule cytoskeleton organization | 80/5968 | 148/18723 | 1.79e-08 | 4.19e-07 | 80 |
GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
GO:0010769111 | Thyroid | PTC | regulation of cell morphogenesis involved in differentiation | 57/5968 | 96/18723 | 2.50e-08 | 5.62e-07 | 57 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:0051017112 | Thyroid | PTC | actin filament bundle assembly | 83/5968 | 157/18723 | 3.73e-08 | 8.18e-07 | 83 |
GO:0034614112 | Thyroid | PTC | cellular response to reactive oxygen species | 82/5968 | 155/18723 | 4.32e-08 | 9.27e-07 | 82 |
GO:0033673111 | Thyroid | PTC | negative regulation of kinase activity | 115/5968 | 237/18723 | 5.98e-08 | 1.26e-06 | 115 |
GO:0061572112 | Thyroid | PTC | actin filament bundle organization | 84/5968 | 161/18723 | 6.75e-08 | 1.40e-06 | 84 |
GO:0032092110 | Thyroid | PTC | positive regulation of protein binding | 51/5968 | 85/18723 | 8.36e-08 | 1.70e-06 | 51 |
GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABL1 | SNV | Missense_Mutation | | c.1375N>C | p.Tyr459His | p.Y459H | P00519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1819N>C | p.Glu607Gln | p.E607Q | P00519 | protein_coding | deleterious_low_confidence(0.02) | benign(0.315) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | SNV | Missense_Mutation | rs780527035 | c.119N>G | p.Asn40Ser | p.N40S | P00519 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.97) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1503C>A | p.Asp501Glu | p.D501E | P00519 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ABL1 | SNV | Missense_Mutation | | c.268N>A | p.Asp90Asn | p.D90N | P00519 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ABL1 | SNV | Missense_Mutation | novel | c.1471A>T | p.Met491Leu | p.M491L | P00519 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Frame_Shift_Ins | novel | c.1125_1126insA | p.Asn377LysfsTer24 | p.N377Kfs*24 | P00519 | protein_coding | | | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | deletion | Frame_Shift_Del | | c.2409delC | p.Arg804GlyfsTer3 | p.R804Gfs*3 | P00519 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Nonsense_Mutation | novel | c.104_105insCCTGGCCTCGTTGTGGAGCGGCTCGTAATCCATCAT | p.Gly35_Gly36insLeuAlaSerLeuTrpSerGlySerTerSerIleMet | p.G35_G36insLASLWSGS*SIM | P00519 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL1 | deletion | Frame_Shift_Del | novel | c.3216_3225delNNNNNNNNNN | p.Ser1073TrpfsTer12 | p.S1073Wfs*12 | P00519 | protein_coding | | | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | DASATINIB | DASATINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | PAZOPANIB | PAZOPANIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | GENISTEIN | GENISTEIN | 9349317 |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | 249565818 | | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Nilotinib | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | vincristine | VINCRISTINE | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Asciminib | ASCIMINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | AZD0530 | SARACATINIB | |